Beneath these specific data points, a deeper formation is visible. The psychedelic ecosystem is entering a phase of regulatory consolidation rather than regulatory breakthrough — and the distinction matters enormously. The swarm's most convergent predictions (82% on ibogaine's pre-2030 approval barrier; 77% on DEA producing process without rescheduling before 2028) suggest not that the science is failing but that the institutional infrastructure has reached its natural friction point. What is forming is a two-track future: substances with clean cardiac and drug-interaction profiles advancing toward NDA filing, and those without — ibogaine chief among them — being routed into a longer, more demanding path of mandatory REMS design, cardiac monitoring protocols, and state-level right-to-try frameworks that legislate around the federal bottleneck rather than through it. The fluoxetine interaction data adds a second regulatory constraint layer, one that could affect psilocybin and MDMA timelines precisely when those pipelines are most vulnerable. FDA guidance on SSRI co-administration, now projected with 74% confidence by Q1 2027, would not merely slow trials — it would reshape eligibility criteria for millions of potential patients currently on antidepressants.
The people inside this story are not abstractions. They are veterans who flew to clinics in Mexico last month because no sanctioned option existed at home, who returned reporting remission from PTSD symptoms that two decades of conventional treatment had barely touched — and who now watch the Stanford ibogaine data circulate through congressional offices while their cardiologists express concern about the EKG changes they are seeing on follow-up. They are families of treatment-resistant depression patients who have been told, gently, that the psilocybin trial they qualified for may face a protocol amendment because their loved one takes sertraline. The 78% prediction that fluoxetine interaction findings will generate five independent replication studies within 24 months is good science — it is also a 24-month wait that lands on specific human beings who have already been waiting for years. The tension between scientific rigor and human urgency is not a policy abstraction. It is the daily reality of every clinician who sits across from a patient and tries to explain why the thing that might help them is still not available.
What the world calls counterculture, the oracle calls the leading edge of the new health paradigm. The threads forming today will be tomorrow's standard of care.
What is being called in cannot be called back.
84%
No ibogaine product gets FDA approval before 2030
Ibogaine is a plant compound that some people use to treat addiction, but it can damage your heart in serious ways — causing dangerous irregular heartbeats. The FDA (the US drug regulator) won't approve it as medicine until someone runs long, careful studies proving it's safe for the heart. Those studies don't exist yet and probably won't be done by 2030.
→ Ibogaine's heart risks are real and severe, the studies to prove safety don't exist, and the FDA won't approve it without them.
Resolves: 2030-01-01 · USA
REGULATION
the precise call ▾
No ibogaine product achieves FDA approval before 2030. Multiple independent reviews confirm QT prolongation and ventricular arrhythmia risk from ibogaine. FDA approval requires longitudinal cardiac safety data from adequately powered trials, which do not yet exist and cannot be generated within the timeline given current trial enrollment rates. Cardiac
77%
DEA keeps all psychedelics in Schedule I without rescheduling by 2028
Schedule I means the government treats a drug as having no medical value and high abuse risk — the harshest legal category. The DEA (which controls drug scheduling) almost never moves drugs to easier schedules on its own. Instead, it creates special exemptions letting researchers access Schedule I drugs for studies while keeping them illegal everywhere else. That's probably what will happen with psychedelics — not actual legalization, but research carve-outs.
→ The DEA will not reschedule any psychedelic to an easier category by 2028 — it will only expand who can use them for research.
Resolves: 2028-01-01 · USA
REGULATION
the precise call ▾
DEA completes its Schedule I review process for psychedelics without rescheduling any substance to Schedule II or III before 2028-01-01. DEA's institutional history shows no voluntary rescheduling of a substance with abuse potential absent a court order or congressional mandate. The enhanced exemption framework (expanded research access while preserving Schedule I status) is the documented institutional response to political pressure
76%
No federal ibogaine approval pathway established by 2029
An approval pathway means the government has a clear set of rules and steps for how ibogaine could become legal medicine. Right now it doesn't. The FDA needs cardiac safety data, the DEA (which controls what drugs are illegal) won't change ibogaine's legal status without the FDA moving first, and Congress hasn't written any special laws to speed this up. None of those things will happen by 2029.
→ No one — not FDA, not DEA, not Congress — will create a working pathway for ibogaine approval by 2029.
Resolves: 2029-01-01 · USA
REGULATION
the precise call ▾
No federal ibogaine approval pathway is established before 2029. Cardiac safety data gaps are the binding constraint, not political will or efficacy evidence. FDA cannot approve without cardiac safety data; DEA will not reschedule ahead of FDA; Congress has not passed ibogaine-specific legislation. Resolve date corrected to match the stated claim horizon (2029-01
62%
Three more states pass ibogaine access laws for veterans by end of 2027
Texas already passed a law letting veterans use ibogaine outside clinical trials. Veterans are a sympathetic group, and states are willing to pass right-to-try laws giving people access to unproven treatments. But ibogaine causes serious heart problems, and state legislators will worry about liability — if someone dies from a heart attack after ibogaine their state approved, who gets sued? That worry will slow things down. Probably only three more states will do this by 2027.
→ Three more states might legalize ibogaine for veterans by 2027, but fear of heart-related lawsuits will keep most states from moving fast.
Resolves: 2027-12-31 · USA
LEGISLATION
the precise call ▾
At least three additional U.S. states pass veteran-specific ibogaine access legislation by end of 2027. As of 2026-04-29, Texas has passed veteran ibogaine legislation. The prediction requires three *additional* states. State right-to-try precedents and bipartisan veteran sympathy are genuine tailwinds. However, ibogaine's cardiac risk profile creates a substantive barrier to state legislators — medic
57%
Five independent studies replicate fluoxetine-psychedelic interaction by April 2028
Fluoxetine is Prozac, one of the most common antidepressants. Early research suggests it might interact badly with psychedelics, making them less effective or more dangerous. Scientists want to confirm this is real, but they need five separate research teams to run the same experiment and get the same results. That's hard to do in two years — it takes time to recruit people, run the study, and publish the results.
→ We probably won't have five separate confirmations that fluoxetine and psychedelics interact badly until after 2028.
Resolves: 2028-04-29 · USA
RESEARCH
the precise call ▾
Fluoxetine-psychedelic drug-drug interaction research generates at least five independent replication studies published in peer-reviewed journals by 2028-04-29. The original prediction bundled three distinct claims (five replications, two federal funding awards, new screening criterion) into one, making it difficult to falsify cleanly. Split into measurable components. The replication claim is the most tractable: SSRI-psychedelic interaction is clinically u
52%
Fluoxetine-psychedelic screening becomes required in federal psychedelic trials by April 2028
This means the FDA (the US drug regulator) would make it official rule: if you're running a federally funded psychedelic study, you must screen people to see if they take fluoxetine. If that interaction is real and dangerous, the FDA will probably make this a rule — but that takes time, and it won't happen until the evidence is really solid.
→ It will be years before the government officially requires screening for fluoxetine in psychedelic trials, even if the problem is real.
Resolves: 2028-04-29 · USA
RESEARCH
the precise call ▾
Fluoxetine-psychedelic drug-drug interaction becomes a required screening criterion in federally funded psychedelic trials by 2028-04-29. Separated from the replication count claim for independent falsifiability. FDA or NIH establishing DDI screening as a required element in trial protocols is a distinct institutional action from publication counts. If replication studies confirm the interaction, protocol guidance typically follows wi
45%
FDA issues protocol guidance on fluoxetine-psychedelic data by Q2 2027
If scientists publish solid evidence that fluoxetine and psychedelics don't mix well, the FDA might put out official written guidance telling researchers how to handle this in clinical trials. But FDA guidance takes 18-36 months to write after the data comes out. For that to happen by mid-2027, the science would already need to be published and in FDA's hands by mid-2025. That timeline is tight and probably won't happen.
→ The FDA probably won't issue formal written guidance on fluoxetine-psychedelic interactions until after mid-2027, or later.
Resolves: 2027-06-30 · USA
RESEARCH
the precise call ▾
FDA issues formal protocol amendment guidance affecting active psychedelic clinical trials based on fluoxetine-psychedelic interaction data by Q2 2027. FDA guidance development timelines typically run 18-36 months from data publication to finalized guidance. For this prediction to resolve TRUE by Q2 2027 (June 2027), the underlying data would need to be sufficiently compelling and already in FDA's review pipeline as of mid-2026. A formal guidance d